These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37682423)

  • 21. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
    BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment.
    Niekel MC; Bipat S; Stoker J
    Radiology; 2010 Dec; 257(3):674-84. PubMed ID: 20829538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
    Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis.
    Schnitzer ML; Buchner J; Biechele G; Grawe F; Ingenerf M; von Münchhausen N; Kaiser CG; Kunz WG; Froelich MF; Schmid-Tannwald C; Rübenthaler J
    Eur J Radiol; 2023 Jun; 163():110803. PubMed ID: 37004464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization.
    Park S; Kim TS; Kang SH; Kim HB; Park JW; Kim SK
    Medicine (Baltimore); 2018 Sep; 97(37):e12311. PubMed ID: 30212970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative imaging for colorectal liver metastases: a nationwide population-based study.
    Elfrink AKE; Pool M; van der Werf LR; Marra E; Burgmans MC; Meijerink MR; den Dulk M; van den Boezem PB; Te Riele WW; Patijn GA; Wouters MWJM; Leclercq WKG; Liem MSL; Gobardhan PD; Buis CI; Kuhlmann KFD; Verhoef C; Besselink MG; Grünhagen DJ; Klaase JM; Kok NFM;
    BJS Open; 2020 Aug; 4(4):605-621. PubMed ID: 32374497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of 18F-FDG PET/CT to select patients with nonresectable colorectal liver metastases for liver transplantation.
    Grut H; Revheim ME; Line PD; Dueland S
    Nucl Med Commun; 2018 Jul; 39(7):621-627. PubMed ID: 29683930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDG-PET reflects tumor viability on SUV in colorectal cancer liver metastasis.
    Watanabe A; Harimoto N; Yokobori T; Araki K; Kubo N; Igarashi T; Tsukagoshi M; Ishii N; Yamanaka T; Handa T; Oyama T; Higuchi T; Shirabe K
    Int J Clin Oncol; 2020 Feb; 25(2):322-329. PubMed ID: 31612350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
    Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
    Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
    Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
    Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A
    Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases.
    Muralidharan V; Kwok M; Lee ST; Lau L; Scott AM; Christophi C
    J Nucl Med; 2012 Sep; 53(9):1345-51. PubMed ID: 22797376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer.
    Sasaki K; Kawasaki H; Sato M; Koyama K; Yoshimi F; Nagai H
    Dig Surg; 2017; 34(1):60-67. PubMed ID: 27454870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan.
    Goshen E; Davidson T; Zwas ST; Aderka D
    Technol Cancer Res Treat; 2006 Feb; 5(1):37-43. PubMed ID: 16417400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG-PET-CT is effective in selecting patients with poor long term survivals for colorectal liver metastases.
    Yip VS; Poston GJ; Fenwick SW; Wieshmann H; Athwal T; Malik HZ
    Eur J Surg Oncol; 2014 Aug; 40(8):995-9. PubMed ID: 24290370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of diagnostic imaging modalities for colorectal liver metastases.
    Bonanni L; de'Liguori Carino N; Deshpande R; Ammori BJ; Sherlock DJ; Valle JW; Tam E; O'Reilly DA
    Eur J Surg Oncol; 2014 May; 40(5):545-550. PubMed ID: 24491289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low Accuracy of Computed Tomography and Positron Emission Tomography to Detect Lung and Lymph Node Metastases of Colorectal Cancer.
    Guerrera F; Renaud S; Schaeffer M; Nigra V; Solidoro P; Santelmo N; Filosso PL; Falcoz PE; Ruffini E; Oliaro A; Massard G
    Ann Thorac Surg; 2017 Oct; 104(4):1194-1199. PubMed ID: 28760464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases.
    Truant S; Huglo D; Hebbar M; Ernst O; Steinling M; Pruvot FR
    Br J Surg; 2005 Mar; 92(3):362-9. PubMed ID: 15672427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.